Novel MS Tx Appears Free of Cardiac Side Effects
BOSTON (MedPage Today) -- An investigational oral drug for multiple sclerosis with the same mechanism as the approved product fingolimod (Gilenya) was highly effective in a phase II trial with seemingly fewer effects on cardiac function than the earlier drug. (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - September 14, 2014 Category: Neurology Source Type: news
Fingolimod (Gilneya) and disease activity
Reanalysis of previous trials show that taking fingolimod were four times more likely than those on placebo to show no evidence of disease activity (NEDA) as those on. NEDA defined as absence of relapses, no MRI lesions, no increase in brain volume loss and no disability progression. Reported at the ACTRIMS/ECTRIMS conference.
Novartis press release
Fingolimod (Gilneya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - September 11, 2014 Category: Neurology Source Type: news
09.11.14 -- FDA News Roundup; Novartis To Present New Data For MS Drug Gilenya
09/11/14Pharmaceutical Online Newsletter (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - September 10, 2014 Category: Pharmaceuticals Source Type: news
Fingolimod May Improve Outcomes of Intracerebral HemorrhageFingolimod May Improve Outcomes of Intracerebral Hemorrhage
Given within 72 hours, this immunomodulator shows promise in small- to moderate-sized deep primary supratentorial ICH. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 13, 2014 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news
MS medications and pregnancy
Summary of some recent studies that have looked at pregnancy outcomes on women using various medications for MS (Betaferon, Tysabri and Gilenya), plus one study where the fathers were on treatment.
MS Research Australia
Pregnancy - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - August 4, 2014 Category: Neurology Source Type: news
Fingolimod May Benefit Intracranial HemorrhageFingolimod May Benefit Intracranial Hemorrhage
The drug, currently used to treat multiple sclerosis, was associated with reduced perihematomal edema and neurologic deficits in a pilot study in patients with ICH. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 21, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Stroke Rounds: An MS Drug for ICH?
(MedPage Today) -- Patients with intracerebral hemorrhage showed improved outcomes when given fingolimod (Gilenya), the oral multiple sclerosis drug, compared with standard care alone in a small trial, researchers said. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 8, 2014 Category: Primary Care Source Type: news
Fingolimod (Gilenya) eligibility extended by NHS England
Fingolimod can now be prescribed on the NHS in England for people who continue to have relapses despite taking beta interferon or glatiramer acetate and for people taking natalizumab who are at high risk of developing progressive multifocal leukoencephalopathy (PML). (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - July 1, 2014 Category: Neurology Source Type: news
Switching From MS Injectables to FingolimodSwitching From MS Injectables to Fingolimod
Dr. Andrew Wilner speaks with lead author Bruce Cree about a study that examined patient satisfaction and clinician perceptions after a switch from injectable MS drugs to fingolimod. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 1, 2014 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
Fingolimod (Gilenya) licence extended
The European Commission has approved the extension of the licence for fingolimod to allow greater access to the drug for people with highly active relapsing remitting multiple sclerosis. (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 11, 2014 Category: Neurology Source Type: news
Fingolimod (Gilenya) licence extended
The European Commission has approved the extension of the licence for fingolimod to allow people to switch to this drug if treatment with other disease modifying drugs has not been successful. Previously people could only switch to fingolimod if they had been treated with beta interferon.
Medical News Today
Disease modifying drugs for relapsing remitting MS - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 10, 2014 Category: Neurology Source Type: news
Fingolimod Reduces Annual Brain Volume Loss in MSFingolimod Reduces Annual Brain Volume Loss in MS
Results of 2 trials show that fingolimod decreases the annual rate of brain volume loss in patients with MS. Setting thresholds compared with healthy adults may help to define disease-free activity. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 6, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Could an MS drug 'erase' traumatic memories?
Conclusion
Despite what the media has reported, the evidence from this study does not prove that it is possible to "erase" painful memories in humans. All we can safely say is that this study has found that the drug fingolimod can reduce fear-related behaviour in genetically modified mice with defects in their immune system.
These mice are known to have impaired acquisition and ability to perform cognitive tasks. Whether fingolimod would have a similar effect on humans who did not have an impaired immune system or cognitive function is unknown.
Changes in memory and anxiety levels were not reported in any of th...
Source: NHS News Feed - May 27, 2014 Category: Consumer Health News Tags: Mental health Neurology Medication Source Type: news
Fingolimod, drug used to treat multiple sclerosis found to help us forget experiences that caused pain
Scientists at Virginia Commonwealth University, US, say fingolimod could now be used to wipe traumatic events, phobias and even sexual hang-ups. (Source: the Mail online | Health)
Source: the Mail online | Health - May 26, 2014 Category: Consumer Health News Source Type: news
Striking a Nerve: MS Drug Provides Clue to PTSD Target
(MedPage Today) -- The multiple sclerosis drug fingolimod (Gilenya) helped erase fear memories in mice, suggesting a new target for anxiety disorders such as post-traumatic stress. (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 25, 2014 Category: Neurology Source Type: news
